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Brief Communication 
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Abstract 
 
High throughput analyses have revealed the presence of activating mutations in the 
AKT1 gene in a subpopulation of meningiomas. We report a female patient with 
multiple intracranial tumor manifestations and histologically verified 
meningotheliomatous meningioma in the lung. The tumor was continuously growing 
at multiple sites despite six surgical resections, radiotherapy and 2 lines of systemic 
therapy. Following detection of an AKT1E17K mutation in 3 independent tumor 
samples by sequencing, treatment with AZD5363, a selective AKT inhibitor, was 
initiated. Ex vivo cultured meningioma cells exhibited sensitivity to the drug as shown 
by pAKT accumulation on immunoblots. Treatment with AZD5363 resulted, for the 
first time, in stable disease and minor radiographic response. The patient has been 
on that treatment for more than one year with ongoing clinical and radiographic 
response. This is the first report of an AKT1-mutant meningioma responding to AKT 
inhibition, suggesting that molecular screening may result in clinical benefit.   
Meningiomas are the most common tumors of the meninges and more frequent than 
primary brain tumors. Recent high throughput analyses have revealed activating 
mutations in the AKT1 gene in a small subpopulation of these tumors, preferentially 
of meningothelial subtype (1-3). Here we report a female patient diagnosed in 1995 
at the age of 37 with left sphenoid wing WHO grade I meningotheliomatous 
meningioma (4). The patient provided written approval of this publication. Local 
resections were done in 1995, 1998 and 2002. In June 2014, an intraorbital 
manifestation was resected which corresponded to a WHO grade I meningioma. In 
September 2014, a left temporal tumor manifestation was partially resected and 
diagnosed as WHO grade III meningioma. Postoperative radiotherapy (50 Gy) was 
given in 1998. In 2009, a thoracic CT scan carried out for prolonged coughing 
showed multiple bilateral pulmonary nodules histologically verified to represent 
somatostatin receptor-positive metastatic meningioma (Figure 1A-D). Octreotide 
therapy was instituted, but resulted in a syndrome reminiscent of experimental 
allergic encephalomyelitis which we interpreted in the context of a history of multiple 
allergies (5).  
In 2011 the patient was exposed to sorafenib, which resulted in regression of 
tumor-associated edema but had to be discontinued because of increased liver 
enzymes. A drug holiday and re-exposure to a lower dose confirmed sorafenib 
intolerance. In 2014 an AKT1E17K mutation was confirmed by PCR and direct 
sequencing in 3 independent tumor samples obtained from 2 sites in the brain and a 
pulmonary meningioma manifestation (Figure 1E).  
Ex vivo cultures from the left temporal meningioma were generated from 
excess surgical material from the patient using a papain dissociation system 
(Worthington Biomedical Corporation, Lakewood, NJ, USA) and kept in Dulbecco's 
Modified Eagle's Medium (DMEM) supplemented with 10% fetal calf serum (FCS) 
until enough cells were available for the experiments. For the experiments, the cells 
were kept in serum-free DMEM and exposed to increasing concentrations of 
AZD5363 for 72 h. Cellular lysates were assessed for phosphoAKT (pAKT), total AKT 
and a downstream target, phospho glycogen synthase kinase (pGSK)-3, by 
immunoblot (6). The following antibodies, diluted 1:1000, from Cell Signaling 
Technology (Boston, Massachusetts, USA) were used: rabbit anti phospho-AKT 
(Thr308), rabbit anti phospho-AKT (Ser473), rabbit anti-AKT and rabbit anti phospho-
GSK-3β (Ser9). The membranes were exposed to HRP-conjugated secondary rabbit-
specific antibodies (Sigma-Aldrich, St Louis, MO, USA). The cell cultures exhibited 
sensitivity to AZD5363, a selective inhibitor of the kinase activity of Akt (7), as verified 
by pAKT accumulation across a concentration range from 1 to 9 µM (Figure 1F), 
although with only moderate growth inhibition and no cytotoxicity at concentrations at 
up to 10 µM as assessed by trypan blue dye exclusion (data not shown).  
Because of further progression at multiple sites (Figure 2A-D), beginning 
November 2014, the patient was started on AZD5363 at 480 mg twice daily in a 4 
days on/3 days off regimen. Treatment was overall well tolerated, with occasional 
minor diarrhea, but no alterations of routine laboratory parameters including complete 
blood count and liver and kidney function tests, and resulted, for the first time, not 
only in stable disease, but a minor radiographic response (Figure 2E,F). The reversal 
of the previous growth trend under AZD5363 treatment for all meningiomas is 
graphically demonstrated in Figure 2G. Reduction in size achieved over the 
treatment period of 17 months varied between 12.5% (orbital meningioma), 11.1% 
(tentorial), and 7.0% for the left temporal meningioma. 
The patient has remained on that treatment for more than one year with 
clinical and radiographic benefit last documented in April 2016. CT scans of the chest 
before initiation of AZD5363 treatment as well as 8 months later demonstrated no 
signs of progression of the intrapulmonary meningioma manifestations 
(Supplementary Figure 1). This is the first documented report of an AKT1-mutant 
metastatic meningioma showing prolonged benefit from targeted therapy using an 
AKT inhibitor. Although this is just a single case observation and long-term efficacy 
and tolerability of AZD5363 remain to be demonstrated, molecular screening and 
targeted treatment of this subgroup of meningioma patients is warranted. 
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Figure Legends 
Figure 1. Histological and molecular features. A. In 1995, biopsy of the sphenoid wing 
tumor revealed a WHO grade I meningothelial meningioma (HE, scale bar: 50 µm). 
B. Intraorbital meningioma with transitional features, including psammoma bodies, 
WHO grade I (HE, scale bar: 50 µm). C. Metastatic meningioma, grade I, within 
pulmonary alveoli (*) (HE, scale bar: 50 µm). D. In 2014, biopsy showed a 
meningioma with atypical features including sheeting and tumor cells with abundant 
eosinophilic cytoplasm and eccentric irregular nuclei, occasionally with discrete 
nucleoli (HE, scale bar: 10 µm). E. Electropherogram depicting the base exchange 
G>A at codon 17 with consecutive amino acid exchange E>K in AKT1. F. Ex vivo 
cultured meningioma cells were exposed to increasing concentrations of AZD5363 
for 72 h. Cellular lysates were assessed for pAKT, total AKT and a down-stream 
target, p-glycogen synthase kinase (GSK) 3, by immunoblot. 
 
Figure 2. Neuroimaging features. Axial and sagittal T1-weighted gadolinium-
enhanced MRI (0.9 mm) on 19-Feb-2009 and 16-Oct-2014 before and 17 months 
after initiation of AZD5363 therapy (18-Apr-2016). A, B. MRI obtained in February 
2009 (A,B) at time of pulmonary meningioma diagnosis depicts left sphenoid wing 
meningioma, cavernous sinus and orbital apex meningiomas, 3 left tentorial incisural 
meningiomas and left temporal meningioma. C, D. Follow-up in October 2014 shows 
progression of all meningiomas despite experimental treatments with octreotide and 
sorafenib. Residual meningiomas are present within orbital apex and at left sphenoid 
wing after partial resection of both orbital apex tumor 6/2014 and of left temporal 
meningioma. E, F. Following 17 months of AZD5363 treatment (4/2016), MRI 
indicates growth arrest and regression in size between 1 and 2.5 mm (- 7 to - 12.5%) 
of all meningiomas best spotted for the incisural meningiomas which become more 
separable. G. Growth patterns of 6 intracranial meningioma manifestations. The 
maximum diameter of each meningioma is shown at the indicated time points. The 
dotted vertical line indicates the last MRI before initiation of AZD5363 treatment. 
Three tumors had a minor size reduction by surgery before start with AZD5363 
therapy which is depicted by the interrupted curves. 
